The efficacy and safety of ipriflavone, a new anti-osteoporotic agent, has been evaluated in an open study in 100 osteoporotic women. Ipriflavone was administered as oral capsules dosed at 200 mg, 3 times a day for 12 months. Ninety women completed the study, and the results indicate that the bone mineral density was increased by 2% and 5.8% after 6 and 12 months, respectively. Pain and rachis mobility seemed to be positively influenced by ipriflavone. Only three women complained of side-effects (gastralgia and nausea) and asked to stop the therapy.
NEW PERSPECTIVES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - IPRIFLAVONE / Moscarini, Massimo; F., Patacchiola; G., Spacca; P., Palermo; Caserta, Donatella; M., Valenti. - In: GYNECOLOGICAL ENDOCRINOLOGY. - ISSN 0951-3590. - STAMPA. - 8:3(1994), pp. 203-207. [10.3109/09513599409072456]
NEW PERSPECTIVES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - IPRIFLAVONE
MOSCARINI, Massimo;CASERTA, Donatella;
1994
Abstract
The efficacy and safety of ipriflavone, a new anti-osteoporotic agent, has been evaluated in an open study in 100 osteoporotic women. Ipriflavone was administered as oral capsules dosed at 200 mg, 3 times a day for 12 months. Ninety women completed the study, and the results indicate that the bone mineral density was increased by 2% and 5.8% after 6 and 12 months, respectively. Pain and rachis mobility seemed to be positively influenced by ipriflavone. Only three women complained of side-effects (gastralgia and nausea) and asked to stop the therapy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
